Author Details :
Volume : 2, Issue : 2, Year : 2016
Article Page : 40-44
Background: Androgenetic alopecia is a very common clinical condition encountered by the dermatologists in their daily practice.
Aims: To study the efficacy of platelet rich plasma in treatment of androgenetic alopecia in male patients.
Settings and design: Observational and interventional study.
Methods: A total of 30 cases of clinically diagnosed male patients with androgenetic alopecia in the age group of 15-50 years constituted the subject material for present study. Detailed history and clinical examination of cases was done. All the routine investigations were carried out.
Statistical analysis used: Data analysis was done by using statistical package for social sciences (SPSS) and “paired t test”.
Results: A total of 30 patients were studied. Large number belonged to the age group 26-30(36.7%) years and 21-25 years(33.3) respectively. Majority are from class 2 to 5, Hamilton Norwood classification of AGA. The family history was positive in 19 cases (63.3%). Frontal, parietal and occipital areas were involved in maximum number of patients i.e. in 20 patients (66.7%). The patients reported clinical improvement in the form of hair count, hair thickness, hair density with statistically significant p-value (p-0.00) after an average of 2-3 sessions.
Conclusion: In our study of 30 patients, 20 patients showed improvement of varying degrees ranging from +1 to +7 according to Jaeschke scale with significant p-value (p-0.00) after treatment with platelet rich plasma(PRP) based upon which we conclude that platelet rich plasma(PRP) is efficacious in the treatment of androgenetic alopecia.
Key-words: Androgenetic alopecia(AGA), Platelet rich plasma(PRP), Males
How to cite : Varma K, Agrawal A, Agrawal M, A study of efficacy of platelet rich plasma in treatment of androgenetic alopecia in male patients. IP Indian J Clin Exp Dermatol 2016;2(2):40-44
Copyright © 2016 by author(s) and IP Indian J Clin Exp Dermatol. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (creativecommons.org)